# Notice of Intent to Sole Source – Life Technologies Corporation

Canonical: https://abierto.us/opportunities/noicc25008722

- Solicitation number: NOI-CC-25-008722
- Notice type: Special notice
- Status: No response deadline
- Department: Department of Health and Human Services
- Agency: National Institutes of Health
- Contracting office: National Institutes of Health - CC (75N900)
- NAICS: 325413 In-Vitro Diagnostic Substance Manufacturing
- Product or service code: 6550 In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
- Place of performance: Bethesda, Maryland
- County: Montgomery County (FIPS 24031). https://abierto.us/counties/montgomery-county-md-24031
- City: Bethesda. https://abierto.us/cities/bethesda-md-2407125
- First posted: August 27, 2025
- Last posted: August 27, 2025
- SAM.gov: https://sam.gov/workspace/contract/opp/00ad38d735664d9baf84834497ae4467/view

## Description

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. This procurement is for AIM V MED CTS 1000ml, DYNABEADS CD3/CD28 CTS 10 ML, HEPES and RPMI 1640 100ML Center for Cellular Engineering (CCE) uses AIM V MED CTS 1000ml, DYNABEADS CD3/CD28 CTS 10 ML, HEPES and RPMI 1640 100ML, material and reagents for patient care responsibilities and these materials are used to manufacture cell-based therapies for patients.

All materials have been validated in manufacturing processes to ensure they are of the appropriate quality and that they produce the desired results. In addition, all materials are approved by the Center for Cellular Engineering Quality Assurance Department. Although the material and reagents are available from several sources, only Life Technologies Corporation has been approved by the Center for Cellular Engineering Quality Assurance Department for use in manufacturing protocols.

Substitution with another vendor/contractor would require requalification of processes to accommodate the changes, which will be both costly and time consuming for the government.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.

Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.

## Publications

- August 27, 2025: Special notice. Notice 00ad38d735664d9baf84834497ae4467. https://sam.gov/workspace/contract/opp/00ad38d735664d9baf84834497ae4467/view

## Points of contact

- Chris Ryssa Nix, ryssa.nix@nih.gov

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/noicc25008722.